Related Experiment Video
Updated: Jun 30, 2026

12:53
Identification of Protein Interaction Partners in Mammalian Cells Using SILAC-immunoprecipitation Quantitative Proteomics
Published on: July 6, 2014
Screening for EphB signaling effectors using SILAC with a linear ion trap-orbitrap mass spectrometer
Guoan Zhang1, David Fenyö, Thomas A Neubert
1Department of Pharmacology and Kimmel Center for Biology and Medicine at the Skirball Institute, New York University School of Medicine, New York, New York 10016, USA.
Journal of Proteome Research
|September 26, 2008
Summary
This study identifies 204 proteins involved in Eph receptor signaling, revealing key players in development, neural plasticity, and cancer progression. Findings highlight known and novel downstream effectors of EphB receptors.
Area of Science:
- Cellular signaling pathways
- Molecular biology
- Cancer research
Background:
- Erythropoietin-producing hepatocellular carcinoma (Eph) receptors are crucial for development, neural plasticity, and cancer.
- Understanding Eph receptor downstream signaling is vital for therapeutic development.
Purpose of the Study:
- To identify and quantify proteins affected by EphB receptor activation.
- To uncover novel components of EphB signaling pathways.
Main Methods:
- Utilized Orbitrap mass spectrometry for high-resolution protein identification.
- Employed stable isotope labeling by amino acids in cell culture (SILAC) for quantitative proteomics.
- Performed antiphosphotyrosine immunoprecipitation to capture signaling proteins after ephrinB1-Fc stimulation.
Main Results:
- Identified and quantified 204 proteins with significantly altered abundance upon ephrinB1-Fc stimulation.
- Confirmed over half of the known downstream effectors of EphB receptors.
- Discovered numerous novel candidate proteins involved in EphB signaling.
Conclusions:
- This proteomic approach successfully mapped key EphB signaling components.
- The identified proteins offer new targets for understanding and potentially treating diseases involving Eph receptors, including cancer.

